Arkolith/Insider Trading/ALGS/Form 4

Blatt Lawrence

Chief Executive Officer, DirectorAligos Therapeutics, Inc. (ALGS) · full profile →Form 4 · filed Feb 28, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2024Grant(A)132K—$0132K
Feb 28, 2024Grant(A)231K—$0231K
Feb 28, 2024Grant(A)58K—$058K
Feb 27, 2024Disposed to issuer(D)323K—$00
Feb 27, 2024Disposed to issuer(D)450K—$00
Feb 27, 2024Disposed to issuer(D)81K—$00

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000098) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML